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RIFAMPICIN-INDUCED ACUTE THROMBOCYTOPENIA 
V V Banu Rekha1, A R Adhilakshmi1, M S Jawahar2 
ABSTRACT 
Rifampicin is an essential component of the treatment regimen 
for tuberculosis. Extensive clinical experience has shown that the 
drug is well tolerated, but on rare occasions it can cause life threatening 
adverse reactions like acute renal failure and thrombocytopenia. At 
the Tuberculosis Research Centre, we have treated more than 8000 
patients with pulmonary and extra-pulmonary tuberculosis with 
rifampicin-containing regimens over the past 30 years and we are 
reporting a case of acute thrombocytopenia probably rifampicin 
induced, in a patient who was retreated for tuberculosis. The physician 
treating tuberculosis patients must be aware of this rare life threatening 
complication, which if detected early, is completely reversible. 
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INTRODUCTION 
Rifampicin is a crucial drug in the treatment 
regimens for tuberculosis. Usually it is well tolerated. 
Apart from minor side effects like abdominal 
discomfort, nausea and vomiting, very rarely it can 
cause life threatening acute renal failure or 
thrombocytopenia1. Rifampicin induced 
thrombocytopenia was first reported in 19702. It is 
usually reversible if detected early and treated 
appropriately. The Tuberculosis Research Centre 
(TRC), Chennai of the Indian Council of Medical 
Research has been conducting controlled clinical trials 
for treatment of tuberculosis since 1956. Since 1974, 
more than 8000 patients with pulmonary and extra- 
pulmonary tuberculosis have been treated with 
rifampicin-containing treatment regimens. We are 
reporting a case of acute thrombocytopenia, probably 
rifampicin induced, in a patient who was being 
retreated for pulmonary tuberculosis at our centre. 
CLINICAL RECORDS 
A 40-year-old female weighing 57 kg attended 
our centre in July 2002 with cough, fever, 
breathlessness and loss of appetite for 2 months. 
About a week earlier, she had completed treatment 
for sputum positive pulmonary tuberculosis at a 
government dispensary with 2 months of isoniazid 600 
mg, rifampicin 450 mg, ethambutol 1200 mg and 
pyrazinamide 1500 mg followed by 4 months of 
isoniazid 600 mg and rifampicin 450 mg thrice weekly. 
She was referred to our centre as she had persistent 
positive sputum smears and cultures for tubercle bacilli. 
The bacilli were resistant to streptomycin, isoniazid 
and ethambutol. The patient was a diabetic for the 
past 10 years and was on Inj. Mixact Bovine insulin 
15 units twice daily. 
On examination she had no anaemia, jaundice or 
pedal edema. She was normotensive and had 
crepitations in both lungs. X-ray chest showed 
infiltration of the right mid and lower zones. Two 
sputum smears were positive for tubercle bacilli by 
fluorescent microscopy, confirmed later by positive 
cultures. Hepatic and renal functions were normal. 
Treatment for sputum positive pulmonary 
tuberculosis was re-started in July 2002 with inj. 
kanamycin l gm thrice weekly, ofloxacin 600 mg, 
rifampicin 600 mg and ethionamide 500 mg daily based 
on the drug susceptibility profile. During the 
supervised treatment of initial 5 months she had missed 
about 18 doses now and then. At the 6th month of 
treatment on request from the patient, we supplied 
the anti-tuberculosis drugs. During this period, she 
complained of fever with chills followed by a rash on 
the face, buccal mucosa, trunk and extremities. Anti- 
tuberculosis drugs were withheld and she was 
prescribed prednisolone tablets 5mg thrice daily. Two 
days later, the anti-tuberculosis drugs were re- 
introduced as the symptoms had subsided. The patient 
then developed hemorrhagic spots on the face, trunk 
and extremities and bleeding per vaginum three days 
later. On examination, she was well oriented, afebrile, 
not anaemic, or dyspnoeic. There were petechial 
eruptions over the face, trunk, extremities, buccal 
mucosa and bleeding per vaginum. Systemic 
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examination and vital signs were normal. All anti- 
tuberculosis drugs were withheld. The patient was 
hospitalised. Investigations revealed a platelet count 
of 15000 cells/cmm and bleeding time of 7 minutes 
and clotting time of 13 minutes. Bone marrow 
aspiration showed megakaryocytosis. Liver and renal 
function tests were within normal limits. A diagnosis 
of acute thrombocytopenic purpura was made. The 
patient was treated with intravenous fluids, inj. 
hydrocortisone hemisuccinate 200 mg iv thrice daily. 
The bleeding subsided and her general condition 
improved with a gradual decline of purpuric spots. 
The steroid dose was gradually tapered and changed 
to oral prednisolone tablets 20 mg thrice daily and 
which was also later tapered. She was discharged in 
February 2003 with a normal platelet count of 2.1 
lakhs/cmm and bleeding time of 2 min. and clotting 
time of 3 min.. As she had 6 months of treatment and 
since her sputum smears and cultures were negative 
for tubercle bacilli consistently after the 1st month of 
treatment, we decided to stop treatment and follow 
her up. Her sputum smears and cultures are negative 
for tubercle bacilli till date. 
DISCUSSION 
The causes of thrombocytopenia include viral 
infections, immune disorders, collagen vascular 
diseases, lymphoproliferative disorders and drugs3. 
Drug induced thrombocytopenia can be caused by 
quinidine, sulphonamides, chemotherapeutic agents, 
penicillin, barbiturates, heparin, digoxin and estrogen3. 
Thrombocytopenia attributed to rifampicin, though 
rare, has been reported in the treatment of pulmonary 
tuberculosis4-7. A literature search revealed a total of 
about 35 cases of rifampicin-induced 
thrombocytopenia which included 15 cases reports. 
Our patient was also receiving kanamycin, ofloxacin 
and ethionamide but damage to the platelets have not 
been reported with these drugs. Hence we concluded 
that the thrombocytopenia was probably rifampicin 
induced. This is consistent with a case reported by 
Ferguson in which the patient developed 
thrombocytopenia after 9 months of daily rifampicin 
therapy .8 
Our patient had tolerated the initial treatment 
with intermittent rifampicin for 6 months without any 
complaints. But after a gap of 10 days when daily 
rifampicin treatment was re-started she developed 
thrombocytopenia after 6 months of treatment. As 
we had supplied the drugs during the 6th month we 
were not sure whether the drugs were consumed daily 
or intermittently. Serious adverse reactions due to 
rifampicin, which are immune complex mediated, are 
mostly encountered during intermittent therapy or 
when there is a gap in treatment9-10. It has been 
postulated that with daily administration of rifampicin, 
there is neutralization of any antibody formed and the 
immune complexes are continuously removed without 
causing any allergic reaction 11. Rifampicin induced 
thrombocytopenia during daily administration though 
rare, has been reported. Unlike our patient, 
retreatment with a daily rifampicin regimen in the 
reported cases resulted in thrombocytopenia in a 
week's time of start of treatment6,7. As we were 
unaware of the rhythm of drug intake in our patient, it 
is not certain that the thrombocytopenia had occurred 
due to daily or intermittent rifampicin intake. 
Although we did not measure rifampicin 
dependent antibodies in our patient, the occurrence 
of thrombocytopenia is attributed to rifampicin 
dependent antibodies. The mechanism hypothesized 
is that, in the presence of the drug, the immune 
complexes non-specifically adsorb to the platelet 
membrane causing platelet damage and rapid removal 
from the circulation2,12. The binding epitope of the IgG 
antibody was found in the glycoprotein Ib / IX complex 
which is the target in rifampicin induced immune 
thrombocytopenia 13. 
Serious adverse reactions during rifampicin 
therapy are usually reversible if detected early and 
treated appropriately. Our patient recovered 
completely on stopping the drug along with supportive 
steroid therapy. Rechallenging with the offending drug 
even in small doses is contraindicated if purpura 
occurs14. There were 3 patients from our centre who 
developed acute renal failure on re-treatment with 
intermittent rifampicin therapy and recovered 
completely on withholding the drug. 
We have treated and followed up more than 
8000 pulmonary and extra-pulmonary tuberculosis 
patients that included both adult and children who 
were treated with rifampicin-containing regimens. The 
regimens in which rifampicin was given daily or 
intermittent throughout or initial daily followed by 
intermittent proved to be extremely safe. But we 
encountered with one patient who developed 
rifampicin-induced thrombocytopenia which enforces 
the fact that the clinician must be aware of these rare 
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complications which are life threatening, but if detected 
early are completely reversible. 
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